Assessment of the Effect of Intravenous Pamidronate in the Treatment of Legg-Calve-Perthes Disease in Children
Novelty in Biomedicine,
Vol. 12 No. 3 (2024),
6 July 2024
,
Page 89- 94
https://doi.org/10.22037/nbm.v12i3.43703
Abstract
Background: Legg-Calvé-Perthes disease (LCPD) presents in childhood with idiopathic avascular necrosis of the femoral head(s), which can lead to disability and the need for corrective surgery at an early age. Bisphosphonates are a group of drugs that prevent osteoclastic bone resorption and may be helpful in the treatment of LCPD. So far, no trial has been conducted to investigate the effect of monthly intravenous pamidronate in the treatment of LCPD in children. Therefore, we assessed this issue in this study.
Materials and Methods: This study was conducted as a clinical trial on children with LCPD who were referred to Mofid Children's Hospital (Iran-Tehran) during 2022 and 2023. Pamidronate was injected monthly and intravenously at a dose of 1 mg/kg/dose. Both groups were the same in terms of the type of treatment received (except pamidronate), the number of visits, and other follow-up parameters. The study was conducted for one year. The significance level was considered less than 0.05.
Results: Forty-seven patients were included in the study. Twenty-one (60%) were in the pamidronate group, and 26 (40%) were in the control group. The mean age in the intervention group was 6.19 ± 1.69 years, and it was 6.15 ± 1.85 years in the control group (P-value=0.944). There was no statistically significant difference in children's gender (P-value = 0.731). Patients with pamidronate had a better overall score than the control group. The overall score in the pamidronate group was 2.37 more than the control group, but this difference was not statistically significant (P value=0.753). The scores of pain, lameness, walking, distance, squat, cross leg, and range of motion (ROM) in the pamidronate group were not significantly different from the control group (P value>0.05).
Conclusion: Pamidronate can improve the clinical results of children with Legg-Calve-Perthes disease, and it is recommended that this drug be used along with the usual treatments for these patients.
- Legg-Calve-Perthes Disease
- Orthopedics
- Pediatrics
- Pamidronate
How to Cite
References
Leroux J, Amara SA, Lechevallier J. Legg-Calvé-Perthes disease. Orthopaedics & Traumatology: Surgery & Research. 2018;104(1):107-12.
Vosmaer A, Pereira RR, Koenderman J, Rosendaal F, Cannegieter S. Coagulation abnormalities in Legg-Calvé-Perthes disease. JBJS. 2010;92(1):121-8.
Rodríguez-Olivas AO, Hernández-Zamora E, Reyes-Maldonado E. Legg–calvé–perthes disease overview. Orphanet Journal of Rare Diseases. 2022;17(1):1-11.
Joseph B. Natural history of early onset and late-onset Legg-Calve-Perthes disease. Vol 31: LWW; 2011:152-5.
Kim HK, Herring JA. Pathophysiology, classifications, and natural history of Perthes disease. Orthopedic Clinics. 2011;42(3):285-95.
Diachkova G, Teplenky M, Diachkov K, Larionova T. Legg-Calvet-Perthes disease and aseptic necrosis of the femoral head: MRI-semiotics of the terminal disease stage with outcome in deforming arthrosis. Age (years). 2020;5(8):9-12.
Nguyen N-AT, Klein G, Dogbey G, McCourt JB, Mehlman CT. Operative versus nonoperative treatments for Legg-Calvé-Perthes disease: a meta-analysis. Journal of Pediatric Orthopaedics. 2012;32(7):697-705.
Mills S, Burroughs KE. Legg Calve Perthes Disease. 2018.
Ganesan K, Bansal P, Goyal A, Roane D. Bisphosphonate. 2017.
Young ML, Little DG, Kim HK. Evidence for using bisphosphonate to treat Legg-Calve-Perthes disease. Clinical Orthopaedics and Related Research®. 2012;470:2462-2475.
McQuade M, Houghton K. Use of bisphosphonates in a case of Perthes disease. Orthopaedic Nursing. 2005;24(6):393-8.
Johannesen J, Briody J, McQuade M, Little DG, Cowell CT, Munns CF. Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg–Calve–Perthes disease. Bone. 2009;45(5):898-902.
Jamil K, Zacharin M, Foster B, et al. Protocol for a randomised control trial of bisphosphonate (zoledronic acid) treatment in childhood femoral head avascular necrosis due to Perthes disease. BMJ paediatrics open. 2017;1(1).
Alos N, Grant R, Ramsay T, et al. High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012;30(22):2760.
Cheng TL, Murphy CM, Cantrill LC, et al. Local delivery of recombinant human bone morphogenetic proteins and bisphosphonate via sucrose acetate isobutyrate can prevent femoral head collapse in Legg-Calve-Perthes disease: a pilot study in pigs. International orthopaedics. 2014;38:1527-33.
Shulman R, Geara AS, Berns JS. Pamidronate versus zoledronic acid for the treatment of multiple myeloma–related hypercalcemia. Kidney International. 2022;101(5):1086.
Yang L, Du S. Efficacy and safety of zoledronic acid and pamidronate disodium in the treatment of malignant skeletal metastasis: a meta-analysis. Medicine. 2015;94(42).
Logan L, Haider S, Brauer C, Miettunen PM. Severe bilateral Legg-Calvé-Perthes resolved with pamidronate in combination with casts, physiotherapy and adductor tenotomy: a pictorial essay over 11 years. BMJ Case Reports CP. 2019;12(9):e229919.
Sivakumar R, Somashekar V, Singhi PK, Chidambaram M. Local Delivery of Single Dose Intra Epiphyseal Bisphosphonates to Prevent the Progression of Legg-Calve-Perthes Disease–Case Series. Journal of Orthopaedic Case Reports. 2020;10(5):65.
Kumar V, Ali S, Verma V, Singh A. Do bisphosphonates alter the clinico-radiological profile of children with Perthes disease? A systematic review and meta-analysis. European Review for Medical & Pharmacological Sciences. 2021;25(15).
- Abstract Viewed: 201 times
- pdf Downloaded: 154 times